Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Herpes Labialis Medicaments

April 4, 2008

Analysis of:Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com

This article fails to explain how Lipsovir will prevent breakouts of new lesions. They say that early use of the ointment in an episode will shorten the duration about 1 1/2 days but where is the evidence that it prevent new episodes? Also there is a lot of viral resistance to acyclovir, which is the anti-viral agent of Lipsovir. Redox Pharmaceutical has a drug, currently in Phase 2 testing that can be used at any time in the episode, cuts the durations of the episode by many days, and has anti-inflammatory properties without using cortisone. Also, there is no evidence of viral resistance to its product. Redox's product is far superior to Lipsovir, although Lipsovir is further along in its clinical tests.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS